Table 3.
Comparison of demographic characteristics, tumor factors, and treatment modalities between male and female patients.
| Female n (%) mean ± SD |
Male n (%) mean ± SD |
P value | |||
|---|---|---|---|---|---|
| Hypertension | 41 | 61.20% | 82 | 48.80% | 0.086 |
| Diabetes | 42 | 62.70% | 94 | 56.00% | 0.345 |
| Underlying cause of liver disease | |||||
| Viral hepatitis | 56 | 83.60% | 122 | 72.60% | 0.077 |
| Nonviral hepatitis | 11 | 16.40% | 46 | 27.40% | |
| Symptoms at presentation | 36 | 53.70% | 87 | 51.80% | 0.787 |
| Noncirrhotic liver | 7 | 10.40% | 37 | 22.00% | 0.049 |
| Number of tumors | |||||
| Single | 33 | 49.30% | 84 | 50.00% | 0.019 |
| Two lesions | 15 | 22.40% | 18 | 10.70% | |
| Multiple (≥3) | 19 | 28.40% | 66 | 39.30% | |
| Metastasis | 5 | 7.50% | 26 | 15.50% | 0.101 |
| Vascular invasion | 7 | 10.40% | 21 | 12.50% | 0.661 |
| Child-Turcotte-Pugh score | |||||
| A | 31 | 46.30% | 104 | 61.90% | 0.08 |
| B | 26 | 38.80% | 49 | 29.20% | |
| C | 10 | 14.90% | 15 | 8.90% | |
| BCLC stages | |||||
| Stage 0 | 2 | 3.00% | 6 | 3.60% | 0.011 |
| Stage A | 32 | 47.80% | 47 | 28.00% | |
| Stage B | 15 | 22.40% | 66 | 39.30% | |
| Stage C | 8 | 11.90% | 34 | 20.20% | |
| Stage D | 10 | 14.90% | 15 | 8.90% | |
| Portal vein thrombosis | 5 | 7.50% | 31 | 18.50% | 0.035 |
| Initial intervention | |||||
| Best supportive care | 23 | 34.30% | 64 | 38.10% | 0.013 |
| Chemoembolization | 13 | 19.40% | 39 | 23.20% | |
| Ablation therapy | 27 | 40.30% | 37 | 22.00% | |
| Sorafenib | 0 | 0.00% | 20 | 11.90% | |
| Surgical resection | 3 | 4.50% | 6 | 3.60% | |
| Transplant | 1 | 1.50% | 2 | 1.20% | |
| AGE | 63 ± 10 | 66 ± 11 | 0.028 | ||
| BMI | 29.75 ± 6.51 | 26.75 ± 5.38 | 0.001 | ||
| Tumor size (cm) | 3.69 ± 2.67 | 6.53 ± 5.63 | 0.000 | ||
| Bilirubin, μmol/L | 31.1 ± 29.8 | 45.7 ± 132.5 | 0.181 | ||
| Albumin, g/L | 31 ± 7 | 34 ± 7 | 0.002 | ||
| AST, U/L | 92 ± 77 | 97 ± 112 | 0.723 | ||
| ALT, U/L | 58 ± 42 | 67 ± 65 | 0.204 | ||
| INR | 1.4 ± 0.7 | 1.2 ± 0.2 | 0.018 | ||
| Creatinine | 90 ± 91.7 | 90 ± 49.3 | 0.997 | ||
| AFP | 13128.1 ± 75 | 10059.3 ± 31 | 0.752 | ||
| Platelets, ×109/L | 174 ± 113 | 212 ± 142 | 0.035 | ||
| MELD | 11.9 ± 5.9 | 11.1 ± 4.7 | 0.312 | ||
SD: standard deviation; BMI: body mass index; MELD: model for end-stage liver disease; AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; INR: international normalized ratio; BCLC: Barcelona Clinic Liver Cancer.